NasdaqGS:MDGLBiotechs
Why Madrigal Pharmaceuticals (MDGL) Is Up 14.1% After Expanding Its MASH Franchise Beyond Rezdiffra
In recent months, Janus Henderson’s Forty Fund highlighted Madrigal Pharmaceuticals’ success with Rezdiffra, the first FDA-approved MASH therapy, while the company also signed a global licensing deal with Suzhou Ribo Life Science and Ribocure for six preclinical siRNA programs targeting metabolic liver disease.
Together, strong early Rezdiffra adoption and an expanded siRNA pipeline suggest Madrigal is moving from a single-product story toward a broader MASH-focused franchise.
Next, we’ll...